

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 18<sup>th</sup> July, 2019

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services,  
25<sup>th</sup> Floor, P. J. Towers, Dalal Street,  
Mumbai-400001

Script ID : 506365

Subject : **SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 for Quarter ended 30<sup>th</sup> June, 2019 as under -


1.	Regulation 33	Un-audited Quarterly Financial Results for the Quarter ended 30/06/2019 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 18/07/2019

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

  
ASHOK SOMANI  
DIRECTOR  
(DIN NO. - 03063364)





**LIMITED REVIEW REPORT**

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30<sup>th</sup> June, 2019**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**NO: C/06/0719**  
**Dated: 11/07/2019**  
**Place: Mumbai**  
**UDIN: 19114222AAAABR5377**



**For M/s VMD & CO.**  
**Chartered Accountants.**  
**FRN: 125002W**

  
**CA Amit Ganpule**  
**Partner**  
**MRN: 114222**

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com


## STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2019

		(Rupees in Thousand)			
Sr. No.	Particulars	Quarter Ended			Year Ended
		30th June 2019	31st March 2019	30th June 2018	31st March 2019
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations				-
II	Other Income	2,831	4,266	1,240	8,225
III	<b>Total Revenue (I + II)</b>	<b>2,831</b>	<b>4,266</b>	<b>1,240</b>	<b>8,225</b>
IV	<b>Expenses</b>				
	(1) Cost Materials consumed	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	(4) Employee Benefits Expenses	405	526	563	2,218
	(5) Depreciation and Amortisation Expenses	-	-	-	47
	(6) Administrative and Other Expenses	923	854	601	3,414
	i) Annual Listing Fees	-	-	310	-
	ii) Travelling Expenses	-	-	268	-
	(7) Finance Costs	-	-	-	-
	<b>Total Expenses</b>	<b>1,328</b>	<b>1,380</b>	<b>1,742</b>	<b>5,679</b>
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	<b>1,503</b>	<b>2,886</b>	<b>(502)</b>	<b>2,546</b>
VI	Exceptional Items	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	<b>1,503</b>	<b>2,886</b>	<b>(502)</b>	<b>2,546</b>
VIII	Extra Ordinary Items	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>1,503</b>	<b>2,886</b>	<b>(502)</b>	<b>2,546</b>
X	Tax Expenses				
	(1) Current Tax	-	460	-	460
	(2) Tax Adjustment Previous Year	-	-	-	23
	(3) Deferred Tax	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	<b>1,503</b>	<b>2,426</b>	<b>(502)</b>	<b>2,063</b>
XII	Profit/(Loss) from discontinuing operations	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	<b>1,503</b>	<b>2,426</b>	<b>(502)</b>	<b>2,063</b>
XVI	Other Comprehensive Income				
	A (i) Itmes that will not be reclassified to profit or loss				
	(ii) Income rax relating to items that will not be reclassified to profit or loss				
	B (i) Itmes that will not be reclassified to profit or loss				
	(ii) Income rax relating to items that will not be reclassified to	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period	<b>1,503</b>	<b>2,426</b>	<b>(502)</b>	<b>2,063</b>
XVIII	<b>Earnings per Share :</b>				
	(1) Basic	<b>1.00</b>	<b>1.62</b>	<b>(0.33)</b>	<b>1.38</b>
	(2) Diluted				

### Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter Ended 30.06.2019 have been reviewed by the Audit Committee in their Meeting held on 18.07.2019 and approved by the Board of Directors of its Meeting held on 18.07.2019. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo - Pharma Laboratories Limited

  
**Ashok Somani**  
 Director



Place : Mumbai

Date : 18th July, 2019

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2019

(Rs. In Thousand)

PARTICULARS	STANDLONE	
	UNAUDITED QUARTER ENDED 30.06.2019	AUDITED YEAR ENDED 31.03.2019
<b>Reconciliation of Profit After Tax as reported earlier:</b>		
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>1,503</b>	<b>2,063</b>
<b>Benefit / (Charge):</b>	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>1,503</b>	<b>2,063</b>

Mumbai, 18th July, 2019



For Chemo - Pharma Laboratories Limited

A handwritten signature in blue ink that reads 'Ashok Somani'.

Ashok Somani  
Director